Peginterferon-Α_2B plus ribavirin is more effective than peginterferon-Α_2A plus ribavirin in menopausal women with chronic hepatitis C. (Q50551487)

15 March 2018

title

Peginterferon-Α_2B plus ribavirin is more effective than peginterferon-Α_2A plus ribavirin in menopausal women with chronic hepatitis C. (English)

1 reference

15 March 2018

1 reference

3

1 reference

15 March 2018

author name string

E Villa

1

1 reference

15 March 2018

C Cammà

2

1 reference

15 March 2018

A Karampatou

4

1 reference

15 March 2018

M Enea

5

1 reference

15 March 2018

S Gitto

6

1 reference

15 March 2018

V Bernabucci

7

1 reference

15 March 2018

L Losi

8

1 reference

15 March 2018

N De Maria

9

1 reference

15 March 2018

B Lei

10

1 reference

15 March 2018

A Ferrari

11

1 reference

15 March 2018

R Vukotic

12

1 reference

15 March 2018

P Vignoli

13

1 reference

15 March 2018

M Rendina

14

1 reference

15 March 2018

A Francavilla

15

1 reference

15 March 2018

publication date

15 March 2012

1 reference

15 March 2018

Journal of Viral Hepatitis

published in

1 reference

15 March 2018

volume

19

1 reference

15 March 2018

issue

9

1 reference

15 March 2018

page(s)

640-649

1 reference

15 March 2018

Inclusion of women, minorities, and children in clinical trials: opinions of research ethics board administrators

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01593.X

Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01593.X

Histological grading and staging of chronic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01593.X

Body fat distribution, relative weight, and liver enzyme levels: a population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01593.X

Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01593.X

Pharmacokinetics of pegylated interferons: what is misleading?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01593.X

Structure, biology, and therapeutic implications of pegylated interferon alpha-2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01593.X

Structural and biophysical characterization of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01593.X

Biopharmaceutical properties of uricase conjugated to neutral and amphiphilic polymers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01593.X

Relationship of body fat topography to insulin sensitivity and metabolic profiles in premenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01593.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01593.X

Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01593.X

Peginterferon alpha-2a (40 kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01593.X

Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01593.X

The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01593.X

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01593.X

Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01593.X

Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01593.X

Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01593.X

Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01593.X

Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01593.X

Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2012.01593.X

10.1111/J.1365-2893.2012.01593.X

21 January 2018

Identifiers

DOI

1 reference

15 March 2018

1 reference

15 March 2018